Teva Appoints New Global Generics Head Amid Massive Integration

Just months after Teva closed the $40.5bn acquisition of Allergan Generics, the company said the man expected to lead the integration, Siggi Olafsson, will step down and be succeeded by Dipankar Bhattacharjee.

Teva Pharmaceutical Industries Ltd. has appointed Dipankar Bhattacharjee as president and CEO of its global generic medicines group, effective immediately, and he will be tasked with an enormous job: overseeing the integration of Allergan PLC’s generic drug business.

The surprising news that the company’s generic medicines head Sigurdur (Siggi) Olafsson will leave the company was announced Dec. 5,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip